Lihat Juga

• Angka tahan hidup pasien kanker paru kelompok bukan sel kecil non skuamosa yang mendapat terapi target Epidermal Growth Factor Receptor-Tyrosin Kinase Inhibitor dan yang mendapat kemoterapi lini pertama di Rumah Sakit Persahabatan = The survival rate of non squamous by non small cell lung carcinoma patiens who are given by target therapy Epidermal Growth Facttor Receptor-Tyrosin Kinase Inhibitors and those given by first line kemotheraphy treatment at Persahabatan Hospital
  oleh: Kasum Supriadi, author, et al.
  Terbitan: (2014)
• Angka tahan hidup pasien kangker paru kelompok bukan sel kecil non skuamosa yang mendapat terapi target Epidermal Growth Factor Receptor-Tyrosin Kinase Inhibitor dan yang mendapat Kemoterapi lini pertama di Rumah sakit Persahabatan = The survival rate of nonsquamous by non small cell lung carcinoma patiens who are given by target therapy epidermal growth facttor receptor-tyrosin kinase inhibitors and those given by first-line kemotheraphy treatment at Persahabatan hospital
  oleh: Kasum Supriadi
  Terbitan: (2014)
• Kapasitas difusi paru terhadap karbon monoksida (DLCO) pada pasien adenokarsinoma paru yang mendapat Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors di Rumah Sakit Persahabatan Jakarta = Lung diffusion capacity (DLCO) of lung adenocarcinoma patients treated with the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Persahabatan Hospital Jakarta, Indonesia
  oleh: Riyadi Sutarto
  Terbitan: (2019)
• Profil Efikasi dan Toksisitas Terapi Target Baru Golongan Epidermal Factor Receptor-Tyrosine Kinase Inhibitor (EGFRTKi)Pada Pasien Kanker Paru Karsinoma Bukan Sel Kecil Non Skuamosa Dengan Mutasi EGFR Positif Dibandingkan Dengan Kemoradioterapi Pada EGFR Wild Type = Profile of Efficacy and Toxicity The New Targeted Therapy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKi) in Non Small Cell Lung Cancer Non-Squamous With Mutated EGFR Compared With Chemoradiotherapy In Wild Type
  oleh: Wiendo Syah Putra Yahya
  Terbitan: (2014)
• Profil efikasi dan toksisitas terapi target baru golongan Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKi) pada pasien kanker paru karsinoma bukan sel kecil non skuamosa dengan mutasi EGFR positif dibandingkan dengan kemoradioterapi pada EGFR Wild type = Profile of efficacy and toxicity the new targeted therapy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKi) in non small cell lung cancer non squamous with mutated EGFR compared with chemoradiotherapy in wild type
  Terbitan: (2014)